109 / 160
661
septiembre de 1999;86(3):242-4.
60. Fraser FC, Fainstat TD. Production of congenital defects in the
off-spring of pregnant mice treated with cortisone; progress
report. PEDIATRICS. octubre de 1951;8(4):527-33.
61. Østensen M, Förger F. Management of RA medications
in pregnant patients. Nat Rev Rheumatol. 9 de junio de
2009;5(7):382-90.
62. Leung YPY, Kaplan GG, Coward S, Tanyingoh D, Kaplan BJ,
Johnston DW, et al. Intrapartum Corticosteroid use Significantly
Increases the Risk of Gestational Diabetes in Women with
Inflammatory Bowel Disease. Journal of Crohn’s and Colitis. 26
de febrero de 2015;9(3):223-30.
63. Beaulieu DB, Ananthakrishnan AN, Issa M, Rosenbaum L, Skaros
S, Newcomer JR, et al. Budesonide induction and maintenance
therapy for Crohn’s disease during pregnancy. Inflamm Bowel
Dis. enero de 2009;15(1):25-8.
64. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The
transplacental passage of prednisone and prednisolone in
pregnancy near term. J Pediatr. noviembre de 1972;81(5):936-
45.
65. Matalon ST, Ornoy A, Lishner M. Review of the potential effects of
three commonly used antineoplastic and immunosuppressive
drugs (cyclophosphamide, azathioprine, doxorubicin on the
embryo and placenta). Reproductive Toxicology. marzo de
2004;18(2):219-30.
66. Polifka JE, Friedman JM. Teratogen update: Azathioprine and
6-mercaptopurine. Teratology. 11 de abril de 2002;65(5):240-
61.
67. Angelberger S, Reinisch W, Messerschmidt A, Miehsler W,
Novacek G, Vogelsang H, et al. Long-term follow-up of babies
exposed to azathioprine in utero and via breastfeeding. Journal
of Crohn’s and Colitis. abril de 2011;5(2):95–100.
68. Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T,
Strohmer H, et al. Azathioprine Treatment and Male Fertility in
Inflammatory Bowel Disease. Gastroenterology. noviembre de
2001;121(5):1048-53.
69. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The
effects of methotrexate on pregnancy, fertility and lactation.
QJM. octubre de 1999;92(10):551-63.
70. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of
methotrexate into human milk. American Journal of Obstetrics
and Gynecology. 1 de abril de 1972;112(7):978-80.
71. French AE, Koren G, Motherisk Team. Effect of methotrexate on
male fertility. Can Fam Physician. mayo de 2003;49:577-8.
72. Petri M. Immunosuppressive Drug Use in Pregnancy.
Autoimmunity. enero de 2003;36(1):51-6.
73. Haugen G, Fauchald P, Sødal G, Halvorsen S, Oldereid N, Moe N.
Pregnancy outcome in renal allograft recipients: influence of
ciclosporin A. Eur J Obstet Gynecol Reprod Biol. 21 de marzo de
1991;39(1):25-9.
74. Reindl W, Schmid RM, Huber W. Cyclosporin A treatment of
steroid-refractory ulcerative colitis during pregnancy: report of
two cases. Gut. 1 de julio de 2007;56(7):1019-9.
75. Angelberger S, Reinisch W, Dejaco C. Prevention of abortion by
ciclosporin treatment of fulminant ulcerative colitis during
pregnancy. Gut. septiembre de 2006;55(9):1364-5.
76. Flechner SM, Katz AR, Rogers AJ, Van Buren C, Kahan BD. The
presence of cyclosporine in body tissues and fluids during
pregnancy. Am J Kidney Dis. enero de 1985;5(1):60-3.
77. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome
after cyclosporine therapy during pregnancy: a meta-analysis.
Transplantation. 27 de abril de 2001;71(8):1051-5.
78. Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V,
et al. Pregnancy after liver transplantation under tacrolimus.
Transplantation. 27 de agosto de 1997;64(4):559-65.
79. French AE, Soldin SJ, Soldin OP, Koren G. Milk Transfer and
Neonatal Safety of Tacrolimus. The Annals of Pharmacotherapy.
junio de 2003;37:815-8.
80. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ,
Moayyedi P. Efficacy of biological therapies in inflammatory
bowel disease: systematic review and meta-analysis. Am J
Gastroenterol. abril de 2011;106(4):644-59, quiz660.
81. Haider S, Knöfler M. Human Tumour Necrosis Factor:
Physiological and Pathological Roles in Placenta and
Endometrium. Placenta. febrero de 2009;30(2):111-23.
82. Torchinsky A, Shepshelovich J, Orenstein H, Zaslavsky Z,
Savion S, Carp H, et al. TNF-alpha protects embryos exposed
to developmental toxicants. Am J Reprod Immunol. marzo de
2003;49(3):159-68.
83. Silver RM, Lohner WS, Daynes RA, Mitchell MD, Branch DW.
Lipopolysaccharide-induced fetal death: the role of tumor-
necrosis factor alpha. Biol Reprod. mayo de 1994;50(5):1108-
12.
84. Salminen A, Paananen R, Vuolteenaho R, Metsola J, Ojaniemi M,
Autio-Harmainen H, et al. Maternal endotoxin-induced preterm
birth in mice: fetal responses in toll-like receptors, collectins,
and cytokines. Pediatr Res. marzo de 2008;63(3):280-6.
85. Kane SV, Acquah LA. Placental Transport of Immunoglobulins:
A Clinical Review for Gastroenterologists Who Prescribe
Therapeutic Monoclonal Antibodies to Women During
Conception and Pregnancy. Am J Gastroenterol. enero de
2009;104(1):228-33.
86. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes
of age. Nat Rev Immunol. 17 de agosto de 2007;7(9):715-25.
87. Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ,
Peppelenbosch MP, et al. High intra-uterine exposure
to infliximab following maternal anti-TNF treatment
during pregnancy. Aliment Pharmacol Ther. 1 de marzo de
2011;33(9):1053-8.
88. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA,
et al. Placental Transfer of Anti-Tumor Necrosis Factor Agents in
Pregnant Patients with Inflammatory Bowel Disease. Clinical
Gastroenterology and Hepatology. noviembre de 2012.
89. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab
in infants and breast milk from nursing mothers receiving
therapy for Crohn’s disease before and after delivery. J Clin
Gastroenterol. agosto de 2009;43(7):613-6.
90. Martin PL, Oneda S, Treacy G. Effects of an Anti-TNF-?
[Fertilidad y embarazo en pacientes con enfermedades inflamatorias intestinales - Dr. Andrés Yarur U.]